Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review

ABSTRACT Introduction: Pneumocystis pneumonia is a potentially life-threatening pulmonary infection that occurs in immunocompromised individuals and HIV-infected patients with a low CD4 cell count. Trimethoprim-sulfamethoxazole has been used as the first-line agent for treatment, but mutations within dihydropteroate synthase gene render potential resistance to sulfamide. Despite advances of combination antiretroviral therapy (cART), Pneumocystis pneumonia continues to occur in HIV-infected patients with late presentation for cART or virological and immunological failure after receiving cART. Areas covered: This review summarizes the diagnosis and first-line and alternative treatment and prophylaxis for Pneumocystis pneumonia in HIV-infected patients. Articles for this review were identified through searching PubMed. Search terms included: ‘Pneumocystis pneumonia’, ‘Pneumocystis jirovecii pneumonia’, ‘Pneumocystis carinii pneumonia’, ‘trimethoprim-sulfamethoxazole’, ‘primaquine’, ‘trimetrexate’, ‘dapsone’, ‘pentamidine’, ‘atovaquone’, ‘echinocandins’, ‘human immunodeficiency virus infection’, ‘acquired immunodeficiency syndrome’, ‘resistance to sulfamide’ and combinations of these terms. We limited the search to English language papers that were published between 1981 and March 2017. We screened all identified articles and cross-referenced studies from retrieved articles. Expert commentary: Trimethoprim-sulfamethoxazole will continue to be the first-line agent for Pneumocystis pneumonia given its cost, availability of both oral and parenteral formulations, and effectiveness or efficacy in both treatment and prophylaxis. Whether resistance due to mutations within dihydropteroate synthase gene compromises treatment effectiveness remains controversial. Continued search for effective alternatives with better safety profiles for Pneumocystis pneumonia is warranted.

[1]  L. La Voie,et al.  Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. , 1990, The New England journal of medicine.

[2]  Mark G Thomas,et al.  Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients , 2009, Scandinavian journal of infectious diseases.

[3]  C. Beard,et al.  Dihydropteroate synthase mutations in Pneumocystis pneumonia: impact of applying different definitions of prophylaxis, mortality endpoints and mutant in a single cohort. , 2013, Medical mycology.

[4]  P. Bookstaver,et al.  Fatal Clindamycin‐Induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome , 2012, Pharmacotherapy.

[5]  S. Meshnick,et al.  Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality. , 2008, Diagnostic microbiology and infectious disease.

[6]  S. Lindbäck,et al.  Aerosolized pentamidine versus i. v. pentamidine for secondary prophylaxis ofPneumocystis carinii pneumonia , 1993, Infection.

[7]  S. Spector,et al.  A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. , 1995, The New England journal of medicine.

[8]  R. Betts,et al.  A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  E. Stone,et al.  Caspofungin: an echinocandin antifungal agent. , 2002, Clinical therapeutics.

[10]  B. Joos,et al.  Monitoring of co-trimoxazole concentrations in serum during treatment of pneumocystis carinii pneumonia , 1995, Antimicrobial agents and chemotherapy.

[11]  J. Shelhamer,et al.  Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. , 1987, The New England journal of medicine.

[12]  S. Kent,et al.  Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity , 1992, AIDS.

[13]  C. Claussen,et al.  HRCT-features of Pneumocystis jiroveci pneumonia and their evolution before and after treatment in non-HIV immunocompromised patients. , 2012, European journal of radiology.

[14]  A. Limper,et al.  Pneumocystis pneumonia. , 2004, The New England journal of medicine.

[15]  H. Einsele,et al.  ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. , 2016, The Journal of antimicrobial chemotherapy.

[16]  Richard D Moore,et al.  Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010. , 2016, The Journal of infectious diseases.

[17]  A. O'donnell,et al.  HIV-related pulmonary infections: a review of the recent literature. , 2003, Current opinion in pulmonary medicine.

[18]  H. Hof,et al.  Pneumocystis jiroveci pneumonia in a patient with Wegener’s granulomatosis treated efficiently with caspofungin , 2008, Mycoses.

[19]  C. Kelly,et al.  Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  S. Kohno,et al.  Adjunctive Corticosteroids for Pneumocystis jirovecii Pneumonia in Non-HIV-infected Patients: A Systematic Review and Meta-analysis of Observational Studies. , 2017, Archivos de bronconeumologia.

[21]  John T Brooks,et al.  Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. , 2009, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[22]  Edmonson Mb,et al.  Fever as an adverse reaction to oral trimethoprim-sulfamethoxazole therapy. , 1992 .

[23]  J. Golden,et al.  Inhaled or reduced-dose intravenous pentamidine for Pneumocystis carinii pneumonia. A pilot study. , 1987, Annals of internal medicine.

[24]  R. Wilkinson,et al.  Clinical Deterioration during Antitubercular Treatment at a District Hospital in South Africa: The Importance of Drug Resistance and AIDS Defining Illnesses , 2009, PloS one.

[25]  C. Kemper,et al.  Low-dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex. , 1990, AIDS.

[26]  D. Podzamczer,et al.  Intermittent Trimethoprim-Sulfamethoxazole Compared with Dapsone-Pyrimethamine for the Simultaneous Primary Prophylaxis of Pneumocystis Pneumonia and Toxoplasmosis in Patients Infected with HIV , 1995, Annals of Internal Medicine.

[27]  K. Traore,et al.  Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients. , 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[28]  W. Hughes,et al.  Treatment of Pneumocystis carinii pneumonitis with trimethoprim-sulfamethoxazole. , 1975, Canadian Medical Association journal.

[29]  S. Buskin,et al.  Trends in perimortal conditions and mortality rates among HIV-infected patients , 2007, AIDS.

[30]  J. Castro,et al.  Management of Pneumocystis Jirovecii pneumonia in HIV infected patients: current options, challenges and future directions. , 2010, HIV/AIDS.

[31]  W. Hughes.  Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  S. Choi,et al.  Clindamycin-primaquine versus pentamidine for the second-line treatment of pneumocystis pneumonia , 2009, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[33]  D. McTavish,et al.  Trimetrexate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of Pneumocystis carinii pneumonia. , 1995, Drugs.

[34]  S. Puli,et al.  Oral clindamycin causing acute cholestatic hepatitis without ductopenia: a brief review of idiosyncratic drug-induced liver injury and a case report , 2015, Journal of community hospital internal medicine perspectives.

[35]  J. Golden,et al.  Intravenous or inhaled pentamidine for treating Pneumocystis carinii pneumonia in AIDS. A randomized trial. , 1990, Annals of internal medicine.

[36]  E. Bow,et al.  Potential consequences of essential drug shortages in Canada: Brain abscess due to Nocardia farcinica associated with dapsone prophylaxis for Pneumocystis jirovecii pneumonia. , 2013, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[37]  S. Hoffman,et al.  Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria , 1995, The Lancet.

[38]  J. Ose,et al.  A Randomized Trial of the Discontinuation of Primary and Secondary Prophylaxis against Pneumocystis carinii Pneumonia after Highly Active Antiretroviral Therapy in Patients with HIV Infection , 2001 .

[39]  E. Eden,et al.  Effect of Corticosteroids on IL1β and TNFα Release by Alveolar Macrophages From Patients With AIDS and Pneumocystis carinii Pneumonia , 1993 .

[40]  P. Reiss,et al.  Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. , 2008, The Lancet. Infectious diseases.

[41]  Francisco Antunes,et al.  Therapeutic Potential of Caspofungin Combined with Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia: A Pilot Study in Mice , 2013, PloS one.

[42]  J. Lundgren,et al.  Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P carinii pneumonia , 1999, The Lancet.

[43]  A. Volpe,et al.  Caspofungin treatment of Pneumocystis pneumonia during conditioning for bone marrow transplantation , 2005, European Journal of Clinical Microbiology and Infectious Diseases.

[44]  G. Fahle,et al.  The use of oral washes to diagnose Pneumocystis carinii pneumonia: a blinded prospective study using a polymerase chain reaction-based detection system. , 2001, The Journal of infectious diseases.

[45]  I. Fong,et al.  Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients , 1995, Antimicrobial agents and chemotherapy.

[46]  T. Kleyman,et al.  A Mechanism for Pentamidine-Induced Hyperkalemia: Inhibition of Distal Nephron Sodium Transport , 1995, Annals of Internal Medicine.

[47]  D. Meyer‐Olson,et al.  Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066) , 2013, Infection.

[48]  U. Schwarz,et al.  Clinical relevance of genetic polymorphisms in the human CYP2C9 gene , 2003, European journal of clinical investigation.

[49]  Sande,et al.  Diagnosis and treatment of Pneumocystis carinii pneumonia. , 1978, Archives of disease in childhood.

[50]  S. Doucette,et al.  Discontinuation of Pneumocystis jirovecii Pneumonia Prophylaxis with CD4 Count <200 Cells/µL and Virologic Suppression: A Systematic Review , 2011, PloS one.

[51]  S. Meshnick,et al.  Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. , 2000, The Journal of infectious diseases.

[52]  Richard D Moore,et al.  Hospitalizations for Metabolic Conditions, Opportunistic Infections, and Injection Drug Use Among HIV Patients: Trends Between 1996 and 2000 in 12 States , 2005, Journal of acquired immune deficiency syndromes.

[53]  S. Lerner,et al.  Trimethoprim/Sulfamethoxazole-Induced Tremor in a Patient with AIDS , 1998, The Annals of pharmacotherapy.

[54]  M. Tsai,et al.  Trends and outcomes of late initiation of combination antiretroviral therapy driven by late presentation among HIV-positive Taiwanese patients in the era of treatment scale-up , 2017, PloS one.

[55]  M. Berkovitch,et al.  Medications and Glucose-6-Phosphate Dehydrogenase Deficiency , 2010, Drug safety.

[56]  J. Zurlo,et al.  Trimethoprim-sulfamethoxazole revisited. , 2003, Archives of internal medicine.

[57]  E. Vittinghoff,et al.  Declining incidence of AIDS-defining opportunistic illnesses: results from 16 years of population-based AIDS surveillance , 2013, AIDS.

[58]  C. Meyer,et al.  Pneumocystis jiroveci pneumonia: high-resolution CT findings in patients with and without HIV infection. , 2012, AJR. American journal of roentgenology.

[59]  T. Navin,et al.  Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. , 1998, The Journal of infectious diseases.

[60]  L. Haddow,et al.  Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. , 2010, The Lancet. Infectious diseases.

[61]  Ye Li,et al.  Adjunctive corticosteroids for the treatment of Pneumocystis jiroveci pneumonia in patients with HIV: A meta-analysis. , 2016, Experimental and therapeutic medicine.

[62]  Ross J. Harris,et al.  Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[63]  C. Beard,et al.  A New Name for Pneumocystis from Humans and New Perspectives on the Host-Pathogen Relationship , 2002, Emerging infectious diseases.

[64]  Y. van der Graaf,et al.  A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. , 1992, The New England journal of medicine.

[65]  M. Coleman,et al.  Drug-Induced Methaemoglobinaemia , 1996, Drug safety.

[66]  J. Montaner,et al.  Atovaquone suspension for treatment of Pneumocystis carinii pneumonia in HIV-infected patients , 2001, AIDS.

[67]  A. Antinori,et al.  Aerosolized pentamidine, cotrimoxazole and dapsone‐pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis , 1995, AIDS.

[68]  S. Follansbee,et al.  Oral Atovaquone Compared with Intravenous Pentamidine for Pneumocystis carinii Pneumonia in Patients with AIDS , 1994, Annals of Internal Medicine.

[69]  L. Worth,et al.  Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools , 2011, Current opinion in infectious diseases.

[70]  M. Stoeckle,et al.  Extrapulmonary Pneumocystis carinii infections in the acquired immunodeficiency syndrome. , 1991, Archives of internal medicine.

[71]  E. Nicastri,et al.  Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment , 2013, AIDS.

[72]  J. Miro,et al.  Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine. , 1993, AIDS.

[73]  J. Montaner,et al.  Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. , 1999, The Journal of infectious diseases.

[74]  V. Cody,et al.  Trimethoprim Resistance of Dihydrofolate Reductase Variants from Clinical Isolates of Pneumocystis jirovecii , 2013, Antimicrobial Agents and Chemotherapy.

[75]  O. Kirk,et al.  Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration , 2014, The Lancet.

[76]  S. Safrin,et al.  The hydroxylamine of sulfamethoxazole and adverse reactions in patients with acquired immunodeficiency syndrome , 1994, Clinical pharmacology and therapeutics.

[77]  M. Kron,et al.  Pentamidine: a review. , 1985, Reviews of infectious diseases.

[78]  Zhe Luo,et al.  Combination of caspofungin and low‐dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients , 2013, Nephrology.

[79]  N. Narita,et al.  Aerosolized pentamidine prophylaxis against AIDS-related Pneumocystis carinii pneumonia and its short- and long-term effects on pulmonary function in the Japanese , 2003, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[80]  J. Bartlett.  Clostridium difficile: clinical considerations. , 1990, Reviews of infectious diseases.

[81]  B. Paice,et al.  Adverse reactions to trimethoprim-sulfamethoxazole. , 1982, Reviews of infectious diseases.

[82]  A. Zolopa,et al.  Early Antiretroviral Therapy Reduces AIDS Progression/Death in Individuals with Acute Opportunistic Infections: A Multicenter Randomized Strategy Trial , 2009, PloS one.

[83]  M. Chabé,et al.  High Prevalence of Pneumocystis jirovecii Dihydropteroate Synthase Gene Mutations in Patients with a First Episode of Pneumocystis Pneumonia in Santiago, Chile, and Clinical Response to Trimethoprim-Sulfamethoxazole Therapy , 2016, Antimicrobial Agents and Chemotherapy.

[84]  J. Phair,et al.  The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. , 1990, The New England journal of medicine.

[85]  Albert Wu,et al.  Comparison of Three Regimens for Treatment of Mild to Moderate Pneumocystis carinii Pneumonia in Patients with AIDS: A Double-Blind, Randomized Trial of Oral Trimethoprim-Sulfamethoxazole, Dapsone-Trimethoprim, and Clindamycin-Primaquine , 1996, Annals of Internal Medicine.

[86]  R. Miller,et al.  Oropharyngeal samples for genotyping and monitoring response to treatment in AIDS patients with Pneumocystis carinii pneumonia. , 1999, Journal of medical microbiology.

[87]  B. Gazzard,et al.  A trial of caspofungin salvage treatment in PCP pneumonia , 2010, Thorax.

[88]  B. Laube,et al.  Bronchodilator pretreatment improves aerosol deposition uniformity in HIV-positive patients who cough while inhaling aerosolized pentamidine. , 1994, Chest.

[89]  C. Nord,et al.  Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. , 2001, The Journal of antimicrobial chemotherapy.

[90]  I. Gorin,et al.  Long-term results of monthly inhaled pentamidine as primary prophylaxis of Pneumocystis carinii pneumonia in HIV-infected patients. , 1993, The American journal of medicine.

[91]  P. Heseltine,et al.  Eflornithine treatment of refractory Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. , 1992, Chest.

[92]  M. Fischl,et al.  Fansidar prophylaxis of Pneumocystis pneumonia in the acquired immunodeficiency syndrome. , 1986, Annals of internal medicine.

[93]  C. Perronne,et al.  Pentamidine-Induced Derangements of Glucose Homeostasis: Determinant roles of renal failure and drug accumulation: A study of 128 patients , 1995, Diabetes Care.

[94]  S. Agrawal,et al.  Dapsone Hypersensitivity Syndrome: A Clinico‐Epidemiological Review , 2005, The Journal of dermatology.

[95]  L. Härmark,et al.  Clindamycin-induced acute generalised exanthematous pustulosis: five cases and a review of the literature. , 2016, The Netherlands journal of medicine.

[96]  J. Falloon,et al.  Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. , 1993, The New England journal of medicine.

[97]  W. Hughes,et al.  Efficacy of Trimethoprim and Sulfamethoxazole in the Prevention and Treatment of Pneumocystis carinii Pneumonitis , 1974, Antimicrobial Agents and Chemotherapy.

[98]  J. Kovacs,et al.  Mutations in the dihydropteroate synthase gene of human-derived Pneumocystis carinii isolates from Italy are infrequent but correlate with prior sulfa prophylaxis. , 2002, The Journal of infectious diseases.

[99]  A. Mocroft,et al.  Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[100]  F. Antunes,et al.  Diagnosis of Pneumocystis pneumonia: evaluation of four serologic biomarkers. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[101]  J. Ioannidis,et al.  A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. , 1996, Archives of internal medicine.

[102]  C. Delves,et al.  The multifunctional folic acid synthesis fas gene of Pneumocystis carinii encodes dihydroneopterin aldolase, hydroxymethyldihydropterin pyrophosphokinase and dihydropteroate synthase. , 1993, European journal of biochemistry.

[103]  R. Barton,et al.  Clindamycin-associated colitis. A prospective study. , 1974, Annals of internal medicine.

[104]  Xuqin Jiang,et al.  Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma after Rituximab-containing regimen: two cases of report and literature review. , 2013, Journal of thoracic disease.

[105]  Y. van der Graaf,et al.  Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. Dutch AIDS Treatment Group. , 1995, The Journal of infectious diseases.

[106]  J. Ashurst,et al.  Pathophysiologic Mechanisms, Diagnosis, and Management of Dapsone-Induced Methemoglobinemia , 2010, The Journal of the American Osteopathic Association.

[107]  M. Sande,et al.  Adjunctive folinic acid with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death. , 1994, The Journal of infectious diseases.

[108]  W. Hughes,et al.  Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. , 1978, The Journal of pediatrics.

[109]  I. Ocaña,et al.  Comparison of high and low doses of trimethoprim-sulfamethoxazole for primary prevention of toxoplasmic encephalitis in human immunodeficiency virus-infected patients. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[110]  G. Wormser,et al.  Trimethoprim‐sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial , 1992, AIDS.

[111]  M. Thorn,et al.  Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. , 1993, The American journal of medicine.

[112]  B. Hirschel,et al.  Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[113]  K. Thursky,et al.  Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014 , 2014, Internal medicine journal.

[114]  K. Sepkowitz,et al.  Progression of Pneumocystis jiroveci pneumonia in patients receiving echinocandin therapy. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[115]  Z. Tong,et al.  Efficacy of caspofungin, a 1,3-β-D-glucan synthase inhibitor, on Pneumocystis carinii pneumonia in rats. , 2014, Medical mycology.

[116]  H. Waskin,et al.  A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. , 1992, The New England journal of medicine.

[117]  P. Kvale,et al.  Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. , 1997, American journal of respiratory and critical care medicine.

[118]  M. Singer,et al.  Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy , 2006, Thorax.

[119]  F. Andersohn,et al.  Systematic Review: Agranulocytosis Induced by Nonchemotherapy Drugs , 2007, Annals of Internal Medicine.

[120]  D. Musher,et al.  Acute kidney injury associated with trimethoprim/sulfamethoxazole. , 2012, The Journal of antimicrobial chemotherapy.

[121]  P. Hopewell,et al.  Aerosolized pentamidine as second line therapy in patients with AIDS and Pneumocystis carinii pneumonia. , 1989, Chest.

[122]  K. Whyte,et al.  Discrimination against people with HIVinfection and AIDS , 1994, BMJ.

[123]  D. Gerding,et al.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) , 2010, Infection Control &#x0026; Hospital Epidemiology.

[124]  J. Roujeau,et al.  The DRESS syndrome: a literature review. , 2011, The American journal of medicine.

[125]  S. Meshnick,et al.  New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. , 2001, JAMA.

[126]  T. Benfield,et al.  Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. , 2009, The Journal of antimicrobial chemotherapy.

[127]  C. Clayman,et al.  3. TOXICITY OF PRIMAQUINE IN CAUCASIANS , 1952 .

[128]  S. Laizure,et al.  Use of low-dose trimethoprim-sulfamethoxazole thrice weekly for primary and secondary prophylaxis of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients , 1991, Antimicrobial Agents and Chemotherapy.

[129]  A. Glatt,et al.  Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. , 1994, The American journal of gastroenterology.

[130]  B. K. Park,et al.  An investigation of the role of metabolism in dapsone-induced methaemoglobinaemia using a two compartment in vitro test system. , 1990, British journal of clinical pharmacology.

[131]  J. Barreto,et al.  Serum Peak Sulfamethoxazole Concentrations Demonstrate Difficulty in Achieving a Target Range: A Retrospective Cohort Study , 2014, Current therapeutic research, clinical and experimental.

[132]  W. El-Sadr,et al.  Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. , 1998, The New England journal of medicine.

[133]  R. Budinsky,et al.  Primaquine-induced hemolytic anemia: formation and hemotoxicity of the arylhydroxylamine metabolite 6-methoxy-8-hydroxylaminoquinoline. , 2001, The Journal of pharmacology and experimental therapeutics.

[134]  J. George,et al.  Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. , 2009, Hematology. American Society of Hematology. Education Program.

[135]  B. Ruf,et al.  Efficacy of clindamycin/primaquine versus trimethoprim/sulfamethoxazole in primary treatment ofPneumocystis carinii pneumonia , 1991, European Journal of Clinical Microbiology and Infectious Diseases.

[136]  M. Lederman,et al.  Risk Factor Analyses for Immune Reconstitution Inflammatory Syndrome in a Randomized Study of Early vs. Deferred ART during an Opportunistic Infection , 2010, PloS one.

[137]  Hong Liu,et al.  A Review on Dapsone Hypersensitivity Syndrome Among Chinese Patients with an Emphasis on Preventing Adverse Drug Reactions with Genetic Testing , 2017, The American journal of tropical medicine and hygiene.

[138]  R. Nieman,et al.  Co-trimoxazole versus dapsone-pyrimethamine for prevention of Pneumocystis carinii pneumonia , 1992, The Lancet.

[139]  M. Madariaga,et al.  Drug-related hepatotoxicity. , 2006, The New England journal of medicine.

[140]  R. Smego,et al.  A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. , 2001, Archives of internal medicine.

[141]  I. Brown,et al.  Acetylator status and tolerance of high-dose trimethoprim-sulfamethoxazole therapy among patients infected with human immunodeficiency virus. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[142]  R. Venuto,et al.  Nephrotoxicity and hyperkalemia in patients with acquired immunodeficiency syndrome treated with pentamidine. , 1989, The American journal of medicine.

[143]  E. Kuijper,et al.  Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim–sulfamethoxazole: lessons from an observational cohort study , 2015, Infection.

[144]  S. Trottier,et al.  Clindamycin with primaquine vs. Trimethoprim-sulfamethoxazole therapy for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS: a multicenter, double-blind, randomized trial (CTN 004). CTN-PCP Study Group. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[145]  M. Perazella,et al.  Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose. , 1996, Clinical nephrology.

[146]  Ke Wang,et al.  PCR Diagnosis of Pneumocystis Pneumonia: a Bivariate Meta-Analysis , 2011, Journal of Clinical Microbiology.

[147]  J. Nielsen,et al.  Aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a controlled, randomized trial. , 1993, Journal of acquired immune deficiency syndromes.

[148]  A. Caliendo,et al.  Molecular and Nonmolecular Diagnostic Methods for Invasive Fungal Infections , 2014, Clinical Microbiology Reviews.

[149]  Hangyong He,et al.  Successful treatment of severe Pneumocystis pneumonia in an immunosuppressed patient using caspofungin combined with clindamycin: a case report and literature review , 2016, BMC Pulmonary Medicine.

[150]  Y. Wali,et al.  Efficacy and Safety of Dapsone Versus Trimethoprim/Sulfamethoxazol for Pneumocystis Jiroveci Prophylaxis in Children With Acute Lymphoblastic Leukemia With a Background of Ethnic Neutropenia , 2017, Journal of pediatric hematology/oncology.

[151]  J. Ruskin,et al.  Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. , 1988, Annals of internal medicine.

[152]  A. Mocroft,et al.  Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV , 2010, AIDS.

[153]  A. Mocroft,et al.  AIDS across Europe, 1994–98: the EuroSIDA study , 2000, The Lancet.

[154]  A. Morris,et al.  Colonization by Pneumocystis jirovecii and Its Role in Disease , 2012, Clinical Microbiology Reviews.

[155]  P. Volberding,et al.  Cutaneous reaction to trimethoprim-sulfamethoxazole in patients with AIDS and Kaposi's sarcoma. , 1983, The New England journal of medicine.

[156]  M. Foisy,et al.  Discontinuing Pneumocystis jirovecii Pneumonia Prophylaxis in HIV-Infected Patients With a CD4 Cell Count <200 cells/mm3 , 2015, The Annals of pharmacotherapy.

[157]  A. Limper,et al.  Current insights into the biology and pathogenesis of Pneumocystis pneumonia , 2007, Nature Reviews Microbiology.

[158]  W. El-Sadr,et al.  A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[159]  E. Murillo,et al.  A young man with myelosuppression caused by clindamycin: a case report , 2014, Journal of Medical Case Reports.

[160]  L. Pagano,et al.  ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. , 2016, The Journal of antimicrobial chemotherapy.

[161]  J E Parrillo,et al.  Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. , 1988, The New England journal of medicine.

[162]  Hartwig Klinker,et al.  Drug monitoring during the treatment of AIDS‐associated Pneumocystis carinii pneumonia with trimethoprim‐sulfamethoxazole , 1998, Journal of clinical pharmacy and therapeutics.

[163]  E. Eden,et al.  Effect of corticosteroids on IL1 beta and TNF alpha release by alveolar macrophages from patients with AIDS and Pneumocystis carinii pneumonia. , 1993, Chest.

[164]  G. Beall,et al.  Desensitization to trimethoprim/sulfamethoxazole in HIV-infected patients. , 1994, The Journal of allergy and clinical immunology.

[165]  Adithya Cattamanchi,et al.  HIV-associated Pneumocystis pneumonia. , 2011, Proceedings of the American Thoracic Society.

[166]  J. Goldman,et al.  Trimethoprim-sulfamethoxazole and hyponatremia. , 1985, Annals of internal medicine.

[167]  M. Jacobson,et al.  Life-threatening immune reconstitution inflammatory syndrome after Pneumocystis pneumonia: a cautionary case series. , 2009, AIDS.

[168]  Yuji Fujikura,et al.  Tratamiento complementario con corticoides en la neumonía por Pneumocystis jirovecii en pacientes no infectados por VIH: revisión sistemática y metanálisis de los estudios observacionales , 2017 .

[169]  Wen-Sen Lee,et al.  Caspofungin salvage therapy in Pneumocystis jirovecii pneumonia. , 2017, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[170]  D. L. Coleman,et al.  Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. , 1986, Annals of internal medicine.

[171]  M. Gari-Toussaint,et al.  Detection of Pneumocystis jirovecii by Quantitative PCR To Differentiate Colonization and Pneumonia in Immunocompromised HIV-Positive and HIV-Negative Patients , 2016, Journal of Clinical Microbiology.

[172]  M. Zolfo,et al.  Mutations in dihydropteroate synthase gene of Pneumocystis carinii in HIV patients with Pneumocystis carinii pneumonia. , 2001, International journal of antimicrobial agents.

[173]  K. Lamp,et al.  Relative Bioavailability of Atovaquone Suspension When Administered with an Enteral Nutrition Supplement , 1998, The Annals of pharmacotherapy.

[174]  M. Kramer,et al.  Successful oral desensitization to trimethoprim-sulfamethoxazole in acquired immune deficiency syndrome. , 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[175]  M. Tsai,et al.  Etiology of pulmonary complications of human immunodeficiency virus-1-infected patients in Taiwan in the era of combination antiretroviral therapy: a prospective observational study. , 2013, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[176]  C. Clayman,et al.  Toxicity of primaquine in Caucasians. , 1952, Journal of the American Medical Association.

[177]  C. del Rio,et al.  Risk factors for AIDS-defining illnesses among a population of poorly adherent people living with HIV/AIDS in Atlanta, Georgia , 2015, AIDS care.

[178]  R. Bartels,et al.  Acute pancreatitis due to sulfamethoxazole-trimethoprim. , 1992, Southern medical journal.

[179]  M. Tsai,et al.  Multicenter Study of Trimethoprim/Sulfamethoxazole-Related Hepatotoxicity: Incidence and Associated Factors among HIV-Infected Patients Treated for Pneumocystis jirovecii Pneumonia , 2014, PloS one.

[180]  R. Couchenour,et al.  Trimethoprim‐Sulfamethoxazole‐Induced Tremor in an Immunocompetent Patient , 1999, Pharmacotherapy.

[181]  E. Andrès,et al.  Agranulocytoses médicamenteuses idiosyncrasiques , 2006 .

[182]  H. Furrer,et al.  Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: Prospective multicentre study , 2004, AIDS.

[183]  L. Jarlsberg,et al.  Severity and outcomes of Pneumocystis pneumonia in patients newly diagnosed with HIV infection: An observational cohort study , 2009, Scandinavian journal of infectious diseases.

[184]  K. Buchacz,et al.  Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994–2005 , 2008, AIDS.

[185]  J. K. Frenkel,et al.  Pneumocystis pneumonia, an immunodeficiency-dependent disease (IDD): a critical historical overview. , 1999, The Journal of eukaryotic microbiology.

[186]  A. Mocroft,et al.  Changes in AIDS-defining illnesses in a London Clinic, 1987-1998. , 1999, Journal of acquired immune deficiency syndromes.

[187]  G A Noskin,et al.  Salvage therapy with clindamycin/primaquine for Pneumocystis carinii pneumonia. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[188]  G. Alterovitz,et al.  HLA-B*51:01 is strongly associated with clindamycin-related cutaneous adverse drug reactions , 2016, The Pharmacogenomics Journal.

[189]  A. Davidson,et al.  Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis: the relative contribution of non-adherence and drug failure , 2000, AIDS.

[190]  J. Jiménez,et al.  Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients. , 1993, AIDS.

[191]  T. Dennis.  Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. , 1986, Annals of internal medicine.

[192]  N. Benowitz,et al.  Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. , 1990, The New England journal of medicine.

[193]  A. Woolf,et al.  Methemoglobinemia: etiology, pharmacology, and clinical management. , 1999, Annals of emergency medicine.

[194]  E. Calderón.  Epidemiology of Pneumocystis infection in Human , 2009 .

[195]  Clindamycin-induced Kidney Diseases: A Retrospective Analysis of 50 Patients. , 2016, Internal medicine.

[196]  J. Fishman,et al.  Pneumocystis Pneumonia in Solid Organ Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[197]  Xiao-Jun Ma,et al.  Lack of response in severe pneumocystis pneumonia to combined caspofungin and clindamycin treatment: a case report. , 2011 .

[198]  Yoshikazu Nakamura,et al.  Relationship between Mutations in Dihydropteroate Synthase of Pneumocystis carinii f. sp.hominis Isolates in Japan and Resistance to Sulfonamide Therapy , 2000, Journal of Clinical Microbiology.

[199]  S. Choi,et al.  Is caspofungin really an effective treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients without human immunodeficiency virus infection? Experiences at a single center and a literature review , 2013, Scandinavian journal of infectious diseases.

[200]  J. Porush,et al.  Trimethoprim-Sulfamethoxazole Induces Reversible Hyperkalemia , 1993, Annals of Internal Medicine.

[201]  M. Balcells,et al.  Successful treatment with echinocandin in an HIV-infected individual failing first-line therapy for Pneumocystis jirovecii pneumonia. , 2011, AIDS.

[202]  E. Dei‐Cas,et al.  Pneumocystis infection in humans: diagnosis and treatment , 2010, Expert review of anti-infective therapy.

[203]  Melanie T. Cushion,et al.  Echinocandin Treatment of Pneumocystis Pneumonia in Rodent Models Depletes Cysts Leaving Trophic Burdens That Cannot Transmit the Infection , 2010, PloS one.

[204]  S. Tasaka,et al.  Recent advances in the diagnosis of Pneumocystis jirovecii pneumonia in HIV-infected adults. , 2013, Expert opinion on medical diagnostics.

[205]  G. Höffken,et al.  Early recurrence of Pneumocystis jiroveci pneumonia in two HIV‐infected patients: Linking infection relapse and immune reconstitution syndrome , 2009, Respirology.

[206]  J. Goldstein,et al.  Enzyme-Mediated Protein Haptenation of Dapsone and Sulfamethoxazole in Human Keratinocytes: I. Expression and Role of Cytochromes P450 , 2006, Journal of Pharmacology and Experimental Therapeutics.

[207]  D. Dooley,et al.  A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[208]  D. Cohn,et al.  Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia. , 1992, Journal of acquired immune deficiency syndromes.

[209]  P. Daniel,et al.  Co-trimoxazole-induced hepatic injury — an analysis of cases with hypersensitivity-like reactions , 2005, Infection.

[210]  F. Derouin,et al.  Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[211]  James J. Goedert,et al.  Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada , 2013, PloS one.

[212]  R. Baughman,et al.  Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol 029/031. , 1994, The Journal of infectious diseases.

[213]  U. Bergman,et al.  Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9 , 2010, European Journal of Clinical Pharmacology.

[214]  J. Borleffs,et al.  Efficacy and Toxicity of Two Doses of Trimethoprim-Sulfamethoxazole as Primary Prophylaxis against Pneumocystis carinii Pneumonia in Patients with Human Immunodeficiency Virus , 1995 .

[215]  E. Dei‐Cas,et al.  Pneumocystis jirovecii Pneumonia , 2011 .

[216]  N. Markowitz,et al.  Pentamidine aerosol versus trimethoprim-sulfamethoxazole for Pneumocystis carinii in acquired immune deficiency syndrome. , 1995, American journal of respiratory and critical care medicine.

[217]  É. Azoulay,et al.  Adjunctive steroid in HIV-negative patients with severe Pneumocystis pneumonia , 2013, Respiratory Research.

[218]  S. Murphey,et al.  Acute pancreatitis associated with pentamidine therapy. , 1981, Archives of internal medicine.

[219]  U. Göbel,et al.  Combined Trimethoprim and Caspofungin Treatment for Severe Pneumocystis Jiroveci Pneumonia in a Five Year Old Boy with Acute Lymphoblastic Leukemia , 2006, Klinische Padiatrie.

[220]  E. Kharasch,et al.  Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers , 1996, Clinical pharmacology and therapeutics.

[221]  SC Chen,et al.  Erratum to: Echinocandin antifungal drugs in fungal infections: a comparison , 2012, Drugs.

[222]  B. Gazzard,et al.  Pneumocystis carinii pneumonia treated with eflornithine in AIDS patients resistant to conventional therapy. , 1990, AIDS.

[223]  Chia-Jui Yang,et al.  Acute psychosis related to use of trimethoprim/sulfamethoxazole in the treatment of HIV-infected patients with Pneumocystis jirovecii pneumonia: a multicentre, retrospective study. , 2012, The Journal of antimicrobial chemotherapy.

[224]  F. Raffi,et al.  Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. Study Group. , 1995, The Journal of infectious diseases.

[225]  Kristina Crothers,et al.  Dihydropteroate Synthase Gene Mutations in Pneumocystis and Sulfa Resistance , 2004, Emerging infectious diseases.

[226]  C. Gaudebout,et al.  Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group. , 1993, The New England journal of medicine.

[227]  M. Edmonson,et al.  Fever as an adverse reaction to oral trimethoprim-sulfamethoxazole therapy. , 1992, The Pediatric Infectious Disease Journal.

[228]  L. La Voie,et al.  Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. , 1988, Journal of the American Medical Association (JAMA).

[229]  B. Marchou,et al.  Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective, randomized, controlled clinical trial. LFPMI Study Group. Ligue Française de Prévention des Maladies Infectieuses. , 1994, Journal of acquired immune deficiency syndromes.

[230]  H. Masur,et al.  Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia. , 1995, The Journal of infectious diseases.

[231]  S. Vesely,et al.  Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. , 2010, Blood.

[232]  Stephen Naylor,et al.  Pneumocystis jirovecii Pneumonia in the Non–HIV-Infected Population , 2016, The Annals of pharmacotherapy.

[233]  G. Bailie,et al.  Pentamidine-Associated Nephrotoxicity and Hyperkalemia in Patients with Aids , 1991, DICP : the annals of pharmacotherapy.

[234]  A. Limper,et al.  Advances in the biology, pathogenesis and identification of Pneumocystis pneumonia , 2008, Current opinion in pulmonary medicine.

[235]  D. Rimland,et al.  Comparison of Trimethoprim‐Sulfamethoxazole, Dapsone, and Pentamidine in the Prophylaxis of Pneumocystis carinii Pneumonia , 1996, Pharmacotherapy.

[236]  M. Merighi,et al.  Twice-weekly dapsone for primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infection: efficacy, safety and pharmacokinetic data. , 1996, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[237]  D. Richman,et al.  A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. , 1990, The New England journal of medicine.

[238]  H. Furrer,et al.  Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. , 2015, The Cochrane database of systematic reviews.

[239]  D. Costagliola,et al.  How does loss to follow‐up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalité 2000 survey and death certificates * , 2009, HIV medicine.

[240]  H. Einsele,et al.  ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. , 2016, The Journal of antimicrobial chemotherapy.

[241]  P. Grossi,et al.  Efficacy of Caspofungin Addition to Trimethoprim-Sulfamethoxazole Treatment for Severe Pneumocystis Pneumonia in Solid Organ Transplant Recipients , 2007, Transplantation.

[242]  John T Brooks,et al.  Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study , 2006, Journal of acquired immune deficiency syndromes.

[243]  C. Beard,et al.  Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P carinii pneumonia in patients with HIV-1: a prospective study , 2001, The Lancet.

[244]  Y. Ubara,et al.  Analysis of factors causing hyperkalemia. , 2007, Internal medicine.